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As the pipeline of new antibiotics slows to a trickle, scientists are developing innovative 
strategies to unearth antibacterial compounds in unexpected places.Resistance of microbial pathogens to 
an increasing number of antibiotics is 
a serious problem. In the US alone, 
90,000 people die every year from 
infections acquired while in the hos-
pital. According to the Infectious Dis-
ease Society of America (IDSA), 70% 
of these deaths have been attributed 
to infection with drug-resistant bac-
teria, in particular methicillin resist-
ant Staphylococcus aureus (MRSA). 
Compounding the problem, the World 
Health Organization warned in Sep-
tember of a new form of tuberculo-
sis, XDR-TB, caused by a multidrug-
resistant strain of Mycobacterium that 
leaves patients virtually untreatable 
with current anti-TB drugs.
Despite this threat, the pipeline of 
new antibiotics approved by the US 
Food and Drug Administration (FDA) is 
running dry. The number of new anti-
biotics is now about 60% lower than 
in the mid-1980s, says Brad Spell-
berg, an infectious disease special-
ist at Harbor-UCLA Medical Center 
in Torrance, CA. “It’s a straight line 
down,” he says. Since the 1960s, only 
two new classes of antibiotics have 
been introduced in the clinic, linezolid 
in 2000 and daptomycin in 2003, 
says Jun Wang, a senior biochemist 
at Merck Research Laboratories in 
Rahway, NJ. The IDSA estimates that 
about a dozen new antibiotics are in 
late clinical testing. But most of them, 
says Spellberg, are “me-too” drugs 
comprising modifications to existing 
compounds or members of known 
classes of antibiotics. “That doesn’t 
help us treat drug resistant bacteria,” 
Spellberg points out, because they 
are often not sufficiently different to 
overcome resistance.
Pharmaceutical companies are less 
interested in developing antibiotics 
than drugs that treat lifelong diseases because people only take antibiot-
ics for a short time, notes Spellberg. 
“There has been at least as many 
drugs developed over the last 12 to 
13 years for HIV as compared to all 
bacterial infections put together,” he 
says. “It’s all about money.” It takes 
250–500 patients treated with an 
antibiotic for every patient on a medi-
cation for a chronic disease to get 
the same return on investment, says 
Christopher Spivey, manager of busi-
ness development at the nonprofit 
Alliance for the Prudent use of Anti-
biotics (APUA) in Boston, MA. “That’s 
why companies have been walking 
away.”
The reason that the antibiotics 
pipeline is running dry is not only 
money but also because the search 
has become more challenging. The 
first antibiotic, discovered by the Brit-
ish microbiologist Alexander Flem-
ing in the 1920s, came from a mold, 
Penicillium notatum. Since then, 
soil-dwelling microorganisms have 
been the traditional source of anti-
biotics. But searching for antibiotics 
the old way—culturing soil bacteria 
and screening them for compounds 
they produce that kill bacterial patho-
gens—means that the same antibi-
otics are discovered over and over 
again, in part because those already 
identified are potent and highly con-
centrated, says Merck’s Wang. We 
have run out of soil bacteria that are 
easy to culture, says Kim Lewis, a 
microbiologist at Northeastern Uni-
versity in Boston, MA: “As with a gold 
mine, you mine it out and it ends.”
Screening Goes up a Notch
Some companies are moving away 
from a dependence on soil bacteria, 
instead screening libraries of syn-
thetic compounds for their antimicro-Cell 127, Debial properties. Pfizer researchers are 
using the genomic sequence infor-
mation of different bacterial strains 
to identify bacterial survival genes. 
They then screen millions of synthetic 
chemicals to find those that interfere 
with the products of these essential 
genes. This approach has yielded 
three new compounds that are now 
in clinical trials and a few more that 
will be soon, says Paul Miller, head of 
Therapeutic Area Research for Anti-
bacterials at Pfizer.
But this strategy is not always suc-
cessful. Between 1995 and 2001, 
GlaxoSmithKline (GSK) did 70 high-
throughput screens of synthetic 
chemical and other libraries for inhibi-
tors of essential bacterial targets. The 
success rate was 4–5 times lower 
than with mammalian cell targets, 
says David Payne, director of micro-
biology at GSK in Collegeville, PA. 
One reason, he says, is that bacterial 
enzymes are harder to inhibit because 
they have evolved for longer and are 
well suited to harsh conditions. Wyeth 
had a similar experience. “Having 
had a similar degree of futility to GSK 
using high-throughput screening, 
we are certainly not going to do that 
ourselves in the future,” says Steven 
Projan, vice president for biological 
technologies at Wyeth Research in 
Cambridge, MA. “Right now we are 
doing very little antibacterial drug 
discovery.” Screening efforts may fail 
because many compounds cannot 
get into bacterial cells or are toxic to 
mammalian cells as well as bacteria 
or because bacteria have transporter 
proteins that can pump out synthetic 
compounds.
Given the mixed success of large 
screening efforts, it may be difficult 
to get big pharmaceutical compa-
nies interested. That’s where APUA cember 1, 2006 ©2006 Elsevier Inc. 867
plans to help by developing a not-for-
profit screening library that would be 
funded by corporate sponsors and 
public money. This would spread 
the risk, and companies would have 
to pay less for the initial screen-
ing effort, says Michael Feldgarden, 
APUA’s research director.
Back to Nature
There are plenty of antibiotic hunt-
ers who have not given up on nature. 
Some research groups are trying to 
isolate rare bacteria or antibiotics 
from soil and are devising methods 
to grow hard-to-culture soil bacteria 
in the lab. Others are isolating DNA 
directly from the soil, using it as a 
blueprint to produce antibiotics, or 
are looking for bacteria in unusual 
places, such as in lichens, seaweed, 
or deep sea mud.
Merck scientists are using a 
new method to screen for antibiot-
ics at such low concentrations that 
they would be missed in traditional 
screens. First, bacteria are made 
more sensitive to potential antibiot-
ics using antisense RNA to induce 
the microbes to make less of a cer-
tain target enzyme that is essential 
for survival. Inhibitors of that target 
enzyme then block the growth of 
the sensitized bacteria to a greater 
extent than the growth of the wild-
type strain. Selecting a target that is 
essential for survival across a broad 
range of bacteria could yield an inhib-
itor capable of blocking the growth of 
many different bacterial strains. The 
Merck team have screened extracts 
of 83,000 bacterial strains from soil 
samples across the globe under three 
different growth conditions. From a 
South African soil sample, they iso-
lated Platensimycin, a member of a 
new class of antibiotics that can kill 
MRSA in vitro. Platensimycin inhibits 
FabF, a bacterial enzyme that synthe-
sizes membrane fatty acids.
The bacterial strain that produced 
Platensimycin can be cultured in the 
lab, but, as Julian Davies, a micro-
biologist at the University of British 
Columbia in Vancouver, points out, at 
least 99% of soil bacteria cannot be 
cultured in vitro. “We know less about 
soil than we do about outer space,” 868 Cell 127, December 1, 2006 ©2006 EDavies says. One gram of soil, he 
says, contains at least 1,000 different 
species of bacteria. That’s why North-
eastern University’s Lewis is develop-
ing ways to culture “unculturable” soil 
bacteria, to find those strains that 
make new antibiotics. “We have a 
protocol to domesticate them,” Lewis 
says. “They don’t know that they are 
not in their environment.” The bac-
teria are cultured in chambers that 
separate them from the environment 
physically, but not chemically. “We 
just bring big buckets of soil in the 
lab and then insert the chambers into 
the soil,” he says. Lewis cofounded 
NovoBiotic Pharmaceuticals, based 
in Cambridge, MA, which uses this 
strategy to find new antibiotics. 
Already, the company has isolated 
thousands of bacterial strains, mainly 
from soil, and currently is focusing 
on about 200 that seem “especially 
interesting,” Lewis says.
Meanwhile, other scientists are not 
even trying to culture recalcitrant soil 
bacteria. Instead, they isolate DNA 
directly from the soil, express the DNA 
in host bacteria in the lab, and then 
screen for antibiotic production—a 
strategy called metagenomics. One 
advantage is that the several dozen 
genes that bacteria use to synthe-
size antibiotics are usually arranged 
together in a cluster. But to get a com-
plete cluster entails isolating a large 
chunk of DNA (about 100 kb), and it 
can be difficult for host organisms in 
the lab to express genes in this DNA. 
Not everyone is convinced that the 
metagenomics strategy will work. 
There is only proof of principle that 
this approach can lead to compounds 
with antibiotic activity, Davies says. “I 
don’t think any of the things that have 
been found will become drugs.”
Jo Handelsman of the University 
of Wisconsin, Madison has devel-
oped a way to screen for metage-
nomic DNA clusters that produce 
small molecules, some of which 
could be antibiotics. A reporter gene 
expressing green fluorescent pro-
tein detects very low concentrations 
of these small molecules inside the 
bacterial cell with the metagenomic 
DNA. Handelsman says this system 
has identified one known antibi-lsevier Inc.otic, which shows that the method 
works. She is currently sequencing 
about 200 bacterial clones contain-
ing metagenomic DNA from soil col-
lected in a remote corner of Alaska, 
which due to the harsh environment 
may yield new bacterial species. 
Handelsman hopes the sequences 
will reveal clones that look like they 
might synthesize new antibiotics.
The Wisconsin-based company 
eMetagen has identified about a 
dozen bacterial clones from Wis-
consin agricultural soil that appear 
to produce compounds with in vitro 
activity against MRSA, says Robert 
Goodman, one of the company’s co-
founders. At least one of them might 
belong to a new class of antibiotics. 
For now, the company is focusing on 
two compounds to determine their 
structure and to do initial toxicity 
testing in animals. The company has 
been able to create libraries with an 
average insert size of 50 kb, he says. 
Next, the company hopes to get bet-
ter expression of the genes in its soil 
bacterial library by switching from a 
gram-negative host (Escherichia coli) 
to a gram-positive host. “Many of the 
genomic DNAs we are accumulat-
ing are probably from gram-positive 
organisms,” Goodman says. 
Not everyone has had success with 
the metagenomics approach, however. 
The Lexington, MA based company 
Cubist Pharmaceuticals tried it for sev-
eral years, but then gave up, says Jeff 
Alder, vice president for drug discovery 
and evaluation. He says too many tech-
nical steps were required, often yield-
ing false positives after a lot of effort. 
“It is just so difficult to get a big piece of 
DNA, get it expressed and then screen 
and [only then] find out what’s valua-
ble,” he says. Instead, Cubist research-
ers are trying to culture soil bacteria 
that are so rare that they have been 
overlooked. Alder says the trick is to 
use indicator bacteria that are resistant 
to most known antibiotics. Only bac-
terial strains that produce new com-
pounds can kill these indicator bacteria 
in test assays. About 1–2 out of every 
10,000 strains tested are able to kill the 
indicator bacteria, says Alder, and 70% 
of these promising bacteria have never 
been described before.
Soil is not the only source of new 
bacterial strains. Brian Austin, a micro-
biologist at Heriot-Watt University 
in Edinburgh, Scotland, has isolated 
bacteria from seaweed and seawater. 
However, they only started to make 
antibiotic compounds when he cul-
tured them on a sponge from his local 
supermarket. So far, he has found two 
new compounds that show antibiotic 
activity against MRSA in vitro. He says 
both antibiotic-producing strains are 
now with a company for further evalu-
ation. Sifting through marine mud, 
oceanographer William Fenical of the 
Scripps Institution in La Jolla, CA has 
found several new bacterial strains that 
produce antibacterial compounds. And 
Davies has isolated about 2000 bacte-
rial strains that grow on lichens, half 
of which show some kind of antibiotic 
activity. Currently, he is focusing on two 
compounds that appear to be new, one 
of which is being further investigated 
by a major pharmaceutical company. 
Fungi, too, have not been forgotten. 
The Danish company Novozymes has 
isolated an antimicrobial peptide called 
plectasin from a fungus that inhab-
its European pine forests. Plectasin 
kills MRSA in mice, and Novozymes 
is planning an early clinical trial of this 
compound in 2008. The Philadelphia-
based company PolyMedix has made 
artificial molecules with similar prop-
erties to antimicrobial peptides. Their 
lead compound can kill both MRSA 
and TB in vitro, and PolyMedix plans 
early clinical trials next year.Despite these encouraging leads, 
one major hurdle for many small 
biotech companies is to pay for 
clinical trials once they have identi-
fied a compound. “We are going to 
have to do this in partnership with 
a drug company,” says eMetagen’s 
Goodman. Novozymes says it will 
pay for phase I trials but is looking 
for partners to take over the project 
after that. PolyMedix also plans to 
fund initial trials but is engaged in 
partnering discussions with major 
pharmaceutical companies, says 
Nicholas Landekic, the compa-
ny’s President and CEO. He says 
the company has raised much of 
the funding from selling stock and 
plans to apply for grants from the 
National Institutes of Health (NIH) to 
pay for part of the cost. But over-
all, he says, such grants could only 
pay for a small portion of the total 
costs of clinical development. Most 
small companies will probably have 
a similar mix of financing, he says, 
although many can’t pay for clinical 
trials at all. “Thus many products 
simply do not ever get developed,” 
Landekic says. At least for this year, 
NIH’s National Institute of Allergy 
and Infectious Diseases (NIAID) is 
offering contracts to support sev-
eral early clinical trials of antibac-
terial drugs, according to Michael 
Kurilla, Director of the Office of Bio-
defense Research Affairs at NIAID. 
“If you have a successful phase I/
phase II that we have supported you Cell 127, Decare going to look very attractive to 
a large pharmaceutical company to 
take on a phase III trial,” he says. 
Spellberg, for his part, calls for leg-
islative incentives to get big phar-
maceutical companies back into 
antibiotic development for the long 
haul. After all, he says, new antibiot-
ics will always be needed. “Bacte-
ria are going to become resistant to 
everything we come up with, it’s just 
a matter of time.”
He may well be right. According to 
a study in Science earlier this year, 
resistance to even the newest antibi-
otics, including synthetic antimicrobi-
als, may already exist in nature. The 
authors screened 480 strains of soil 
bacteria from different environments 
against 21 antibiotics and found them 
to be resistant, on average, to 7 antibi-
otics, even those bacteria from remote 
areas. Many were resistant to the new 
semisynthetic antibiotic tigecycline, 
which was approved for use only last 
year. While the findings sound a note 
of doom, they do give us the opportu-
nity to look for resistance mechanisms 
in nature as an early warning system, 
before they are found in hospital bac-
teria, says Gerard D. Wright of McMas-
ter University in Ontario, Canada, who 
led the study. “Resistance is inevita-
ble,” Wright says. “There is no such 
thing as an irresistible antibiotic; no 
matter what chemistry you can think 
of, because the organisms have been 
around for so long, they figured out a 
way to survive. And they will.”ember 1, 2006 ©2006 Elsevier Inc. 869
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